Allogenic mouse cell vaccine inhibits lung cancer progression by inhibiting angiogenesis

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.21442.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim J-H, Arvis CD, Ahn M-J, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50. doi:10.1016/S0140-6736(15)01281-7.
   PubMed Web of Science ®Google Scholar
• Velcheti V, Chandwani S, Chen X, Pietanza MC, Piperdi B, Burke T. Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS >/=50%) metastatic NSCLC at US oncology practices. Immunotherapy. 2019;11(18):1541–54. doi:10.2217/imt-2019-0177.
   PubMed Web of Science ®Google Scholar
• Janning M, Loges S. Anti-angiogenics: their value in lung cancer therapy. Oncol Res Treat. 2018;41:172–80. doi:10.1159/000488119.
   PubMed Web of Science ®Google Scholar
• Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu Y-L, Brustugun OT, Crinò L, et al. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J Thoracic Oncol: Off Publ Int Assoc Study Lung Cancer. 2017;12(2):194–207. doi:10.1016/j.jtho.2016.10.003.
   Google Scholar
• Folkman J. Role of angiogenesis in tumour growth and metastasis. Semin Oncol. 2002;29:15–18. doi:10.1053/sonc.2002.37263.
   PubMed Web of Science ®Google Scholar
• Van Dreden P, Epsilonlalamy I, Gerotziafas GT. The role of tissue factor in cancer-related hypercoagulability, tumor growth, angiogenesis and metastasis and future therapeutic strategies. Crit Rev Oncog. 2017;22(3–4):219–48. doi:10.1615/CritRevOncog.2018024859.
   PubMedGoogle Scholar
• Yang Y, Jin G, Liu H, Liu K, Zhao J, Chen X, Wang D, Bai R, Li X, Jang Y, et al. Metformin inhibits esophageal squamous cell carcinoma-induced angiogenesis by suppressing JAK/STAT3 signaling pathway. Oncotarget. 2017;8(43):74673–87. doi:10.18632/oncotarget.20341.
   PubMedGoogle Scholar
• Jin G, Yang Y, Liu K, Zhao J, Chen X, Liu H, Bai R, Li X, Jiang Y, Zhang X, et al. Combination curcumin and (-)-epigallocatechin-3-gallate inhibits colorectal carcinoma microenvironment-induced angiogenesis by JAK/STAT3/IL-8 pathway. Oncogenesis. 2017;6(10):e384. doi:10.1038/oncsis.2017.84.
   PubMedGoogle Scholar
• Lopes A, Vandermeulen G, Preat V. Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. J Exp Clin Cancer Res: CR. 2019;38(1):146. doi:10.1186/s13046-019-1154-7.
   PubMed Web of Science ®Google Scholar
• Strioga MM, Darinskas A, Pasukoniene V, Mlynska A, Ostapenko V, Schijns V. Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use? Vaccine. 2014;32(32):4015–24. doi:10.1016/j.vaccine.2014.05.006.
   PubMed Web of Science ®Google Scholar
• Pinto MP, Sotomayor P, Carrasco-Avino G, Corvalan AH, Owen GI. Escaping Antiangiogenic Therapy: strategies Employed by Cancer Cells. Int J Mol Sci. 2016;17(9):1489.
   Web of Science ®Google Scholar
• Rahma OE, Hodi FS. The intersection between tumor angiogenesis and immune suppression. Clin Cancer Res: Off J Am Assoc Cancer Res. 2019;25(18):5449–57. doi:10.1158/1078-0432.CCR-18-1543.
   PubMed Web of Science ®Google Scholar
• Zhao J, Lu J, Liu YQ, Yang HY, Huang YT, Zhao JM, Li S, Zhai J-M, Zhao M-Y, Zhang X, et al. Study on the specific immunity induced by dendritic cell vaccine loading allogeneic microvascular endothelial cell bEnd.3 antigen against U14 cervical cancer cell in mice. Zhonghua Fu Chan Ke Za Zhi. 2011;46(1):52–57.
   PubMedGoogle Scholar
• Lu J, Tang Y, Farshidpour M, Cheng Y, Zhang G, Jafarnejad SM, Yip A, Martinka M, Dong Z, Zhou J, et al. JWA inhibits melanoma angiogenesis by suppressing ILK signaling and is an independent prognostic biomarker for melanoma. Carcinogenesis. 2013;34(12):2778–88. doi:10.1093/carcin/bgt318.
   PubMed Web of Science ®Google Scholar
• Lu J, Tang Y, Cheng Y, Zhang G, Yip A, Martinka M, Dong Z, Zhou J, Li G. ING4 regulates JWA in angiogenesis and their prognostic value in melanoma patients. Br J Cancer. 2013;109(11):2842–52. doi:10.1038/bjc.2013.670.
   PubMed Web of Science ®Google Scholar
• Cao Y. Future options of anti-angiogenic cancer therapy. Chin J Cancer. 2016;35(1):21. doi:10.1186/s40880-016-0084-4.
   PubMedGoogle Scholar
• Zhao J, Lu J, Zhou L, Dong Z. Efficacy for lung metastasis induced by the allogeneic bEnd3 vaccine in mice. Hum Vaccin Immunother. 2018;14(5):1294–304. doi:10.1080/21645515.2018.1427532.
   PubMed Web of Science ®Google Scholar
• Wang J, Yang L, Liang F, Chen Y, Yang G. Integrin alpha x stimulates cancer angiogenesis through PI3K/Akt signaling-mediated VEGFR2/VEGF-A overexpression in blood vessel endothelial cells. J Cell Biochem. 2019;120(2):1807–18. doi:10.1002/jcb.27480.
   PubMed Web of Science ®Google Scholar
• Al-Abd AM, Alamoudi AJ, Abdel-Naim AB, Neamatallah TA, Ashour OM. Anti-angiogenic agents for the treatment of solid tumors: potential pathways, therapy and current strategies - A review. J Adv Res. 2017;8(6):591–605. doi:10.1016/j.jare.2017.06.006.
   PubMed Web of Science ®Google Scholar
• Niu G, Chen X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets. 2010;11(8):1000–17. doi:10.2174/138945010791591395.
   PubMed Web of Science ®Google Scholar
• Dey N, De P, Brian LJ. Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors. Am J Transl Res. 2015;7:1675–98.
   PubMed Web of Science ®Google Scholar
• Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. Lancet. 2016;388(10043):518–29. doi:10.1016/S0140-6736(15)01088-0.
   PubMed Web of Science ®Google Scholar
• Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu C-J, Huang M-J, Lou -Y-Y. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med. 2000;6(10):1160–66. doi:10.1038/80506.
   PubMed Web of Science ®Google Scholar
• Lu M, Yao Q, Liu H, Zhong W, Gao J, Si C, Zhou L, Zhang S, Xu M. Combination of human umbilical vein endothelial cell vaccine and docetaxel generates synergistic anti-breast cancer effects. Cancer Biother Radiopharm. 2019;34(7):464–71. doi:10.1089/cbr.2018.2721.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhao J, Yang Y, Jin G, Zhang X, Wang D, Xie C, Liu K, Chen X, Li X. Human umbilical vein endothelial cell vaccine suppresses the angiogenesis of esophageal squamous cell carcinoma in a humanized mouse model. Oncol Rep. 2018;40(5):3006–14. doi:10.3892/or.2018.6653.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Xie C, Wang D, Yang Y, Liu H, Liu K, Zhao J, Chen X, Zhang X, Yang W, et al. Improved antitumor efficacy of combined vaccine based on the induced HUVECs and DC-CT26 against colorectal carcinoma. Cells. 2019;8(5):494. doi:10.3390/cells8050494.
   PubMed Web of Science ®Google Scholar
• Okaji Y, Tsuno NH, Kitayama J, Saito S, Takahashi T, Kawai K, Yazawa K, Asakage M, Hori N, Watanabe T, et al. Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci. 2004;95(1):85–90. doi:10.1111/j.1349-7006.2004.tb03175.x.
   PubMed Web of Science ®Google Scholar
• Yoneyama S, Okaji Y, Tsuno NH, Kawai K, Yamashita H, Tsuchiya T, Yamada J, Sunami E, Osada T, Kitayama J, et al. A study of dendritic and endothelial cell interactions in colon cancer in a cell line and small mammal model. Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2007;33(10):1191–98. doi:10.1016/j.ejso.2007.01.013.
   Google Scholar
• Liu SH, Zhang M, Zhang WG. Strategies of antigen-specific T-cell-based immunotherapy for cancer. Cancer Biother Radiopharm. 2005;20(5):491–501. doi:10.1089/cbr.2005.20.491.
   PubMed Web of Science ®Google Scholar
• Griffioen AW. Anti-angiogenesis: making the tumour vulnerable to the immune system. Cancer Immunol ImmunoTher: CII. 2008;57(10):1553–58. doi:10.1007/s00262-008-0524-3.
   PubMed Web of Science ®Google Scholar
• Mufson RA. Tumor antigen targets and tumour immunotherapy. Front Biosci: J Virtual Lib. 2006;11:337–43. doi:10.2741/1801.
   PubMed Web of Science ®Google Scholar
• Boehm T, Folkman J, Browder T, O’Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390(6658):404–07. doi:10.1038/37126.
   PubMed Web of Science ®Google Scholar
• Alessi P, Ebbinghaus C, Neri D. Molecular targeting of angiogenesis. Biochim Biophys Acta. 2004;1654(1):39–49. doi:10.1016/j.bbcan.2003.08.001.
   PubMed Web of Science ®Google Scholar
• Bloemendal HJ, Logtenberg T, Voest EE. New strategies in anti-vascular cancer therapy. Eur J Clin Invest. 1999;29(9):802–09. doi:10.1046/j.1365-2362.1999.00534.x.
   PubMed Web of Science ®Google Scholar
• Goh PP, Sze DM, Roufogalis BD. Molecular and cellular regulators of cancer angiogenesis. Curr Cancer Drug Targets. 2007;7(8):743–58. doi:10.2174/156800907783220462.
   PubMed Web of Science ®Google Scholar
• Sato T, Takusagawa K, Asoo N, Kumano N, Hasuike M, Konno K. Conversion of Lewis lung carcinoma into ascitic form. Oncology. 1989;46(3):188–92. doi:10.1159/000226712.
   PubMed Web of Science ®Google Scholar
• Wen J, Fu AF, Chen LJ, Xie XJ, Yang GL, Chen XC, Wang YS, Li J, Chen P, Tang MH, et al. Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumour model. Int J Cancer. 2008;124:2709–18. doi:10.1002/ijc.24244.
   Web of Science ®Google Scholar
• Hodish I, Tal R, Shaish A, Varda-Bloom N, Greenberger S, Rauchwerger A, Breitbart E, Bangio L, Ben-Shushan D, Pfeffer R, et al. Systemic administration of radiation-potentiated anti-angiogenic gene therapy against primary and metastatic cancer based on transcriptionally controlled HSV-TK. Cancer Biol Ther. 2009;8(5):424–32. doi:10.4161/cbt.8.5.7589.
   PubMed Web of Science ®Google Scholar
• Chen XY, Zhang W, Zhang W, Wu S, Bi F, Su YJ, Tan XY, Liu JN, Zhang J. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumour vasculature with both cellular and humoral immunity. Clin Cancer Res: Off J Am Assoc Cancer Res. 2006;12:5834–40. doi:10.1158/1078-0432.CCR-06-1105.
   PubMed Web of Science ®Google Scholar
• Xiang R, Mizutani N, Luo Y, Chiodoni C, Zhou H, Mizutani M, Ba Y, Becker JC, Reisfeld RA. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumour eradication. Cancer Res. 2005;65:553–61.
   PubMed Web of Science ®Google Scholar
• Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumour growth. Nat Med. 2002;8(12):1369–75. doi:10.1038/nm1202-794.
   PubMed Web of Science ®Google Scholar
• He QM, Wei YQ, Tian L, Zhao X, Su JM, Yang L, Lu Y, Kan B, Lou -Y-Y, Huang M-J. Inhibition of tumour growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem. 2003;278(24):21831–36. doi:10.1074/jbc.M300880200.
   PubMed Web of Science ®Google Scholar
• Tan GH, Wei YQ, Tian L, Zhao X, Yang L, Li J, He QM, Wu Y, Wen YJ, Yi T, et al. Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen. Eur J Immunol. 2004;34:2012–21. doi:10.1002/eji.200424933.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Bosch ML, Salgaller ML. Current methods for loading dendritic cells with tumour antigen for the induction of antitumor immunity. J Immunother. 2002;25:289–303. doi:10.1097/00002371-200207000-00001.
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2(1):52–58. doi:10.1038/nm0196-52.
   PubMed Web of Science ®Google Scholar
• Boudreau J, Koshy S, Cummings D, Wan Y. Culture of myeloid dendritic cells from bone marrow precursors. J Visualized Exp: JoVE. 2008;(17):769.
   PubMedGoogle Scholar
• Krawczyk P, Wojas K, Milanowski P, Rolinski J. Myeloid and lymphoid dendritic cells and cytotoxic T lymphocytes in peripheral blood of non-small cell lung cancer patient–a pilot study. Adv Med Sci. 2006;51:160–63.
   PubMedGoogle Scholar
• Liu WJ, Du Y, Wen R, Yang M, Xu J. Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. Pharmacol Ther. 2020;206:107438.
   PubMed Web of Science ®Google Scholar
• Catacchio I, Scattone A, Silvestris N, Mangia A. Immune prophets of lung cancer: the prognostic and predictive landscape of cellular and molecular immune markers. Transl Oncol. 2018;11:825–35.
   PubMed Web of Science ®Google Scholar